Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial
During exit interviews, patients receiving glepaglutide reported improvements in well-being across multiple domains, noting meaningful reductions in PS volume and a reduced impact of SBS-IF on daily life, which was proportionally greater than in those receiving placebo. These findings underscore the patient-reported positive experiences of glepaglutide and its beneficial effects.
Authors
- Anna Rydén (ORCID: https://orcid.org/0000-0001-8106-5751)
- Constance Mubekapi‐Musadaidzwa (ORCID: https://orcid.org/0000-0003-4430-7461)
- David F. Mercer (ORCID: https://orcid.org/0000-0003-1557-1773)
- Mark Berner‐Hansen
- B. Kloster
- Palle Bekker Jeppesen
Institutions
- Nebraska Medical Center (US)
- Danish Maritime Authority (DK)
- Bispebjerg Hospital (DK)
- Rigshospitalet (DK)
- Zealand Pharma (Denmark) (DK)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Nutrition in Clinical Practice
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1002/ncp.70109
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00